Is KMSTF or QYLD a better dividend investment in 2026?

KMSTF currently yields 62.31% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: KMSTF offers higher current income.

What is the dividend yield difference between KMSTF and QYLD?

KMSTF has a forward dividend yield of 62.31% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 50.39 percentage points.

Home › Compare › KMSTF vs QYLD

KMSTF vs QYLD: Dividend Comparison 2026

KMSTF yields 62.31% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 KMSTF wins by $703.6K in total portfolio value

INVESTMENT

TIME HORIZON10 years

KMSTF

● Live price

62.31%

Share price

$3.21

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$729.0K

Annual income

$175,361.30

Full KMSTF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — KMSTF vs QYLD

📍 KMSTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	KMSTF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, KMSTF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

KMSTF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KMSTF

Annual income on $10K today (after 15% tax)

$5,295.95/yr

After 10yr DRIP, annual income (after tax)

$149,057.10/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, KMSTF beats the other by $144,246.69/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KMSTF + QYLD for your $10,000?

KMSTF: 50%QYLD: 50%

100% QYLD50/50100% KMSTF

Portfolio after 10yr

$377.2K

Annual income

$90,510.31/yr

Blended yield

23.99%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KMSTF buys

QYLD buys

No recent congressional trades found for KMSTF or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricKMSTFQYLD

Forward yield	62.31% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$729.0K ✓	$25.4K
Annual income after 10y	$175,361.30 ✓	$5,659.31
Total dividends collected	$608.8K ✓	$27.1K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: KMSTF vs QYLD ($10,000, DRIP)

Year	KMSTF Portfolio	KMSTF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$16,931	$6,230.53	$10,352	$1,192.36	+$6.6K → KMSTF
2	$27,974	$9,858.52	$10,830	$1,347.57	+$17.1K → KMSTF
3	$45,156	$15,223.51	$11,460	$1,539.07	+$33.7K → KMSTF
4	$71,283	$22,966.14	$12,275	$1,777.84	+$59.0K → KMSTF
5	$110,155	$33,882.50	$13,323	$2,078.95	+$96.8K → KMSTF
6	$166,800	$48,934.07	$14,667	$2,463.34	+$152.1K → KMSTF
7	$247,726	$69,249.85	$16,396	$2,960.57	+$231.3K → KMSTF
8	$361,186	$96,119.21	$18,631	$3,612.97	+$342.6K → KMSTF
9	$517,443	$130,974.20	$21,548	$4,482.15	+$495.9K → KMSTF
10	$729,026	$175,361.30	$25,398	$5,659.31	+$703.6K → KMSTF

KMSTF vs QYLD: Complete Analysis 2026

KMSTF — Stock

Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.

Full KMSTF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this KMSTF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KMSTF vs SCHD KMSTF vs JEPI KMSTF vs O KMSTF vs KO KMSTF vs MAIN KMSTF vs XYLD KMSTF vs JEPQ KMSTF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.